8,696 Shares in Qiagen (NYSE:QGEN) Acquired by Capstone Investment Advisors LLC

Capstone Investment Advisors LLC bought a new position in Qiagen (NYSE:QGEN) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 8,696 shares of the company’s stock, valued at approximately $395,000.

Several other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC increased its holdings in shares of Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after purchasing an additional 500 shares during the period. Toronto Dominion Bank bought a new position in Qiagen in the 2nd quarter worth about $27,000. Massmutual Trust Co. FSB ADV raised its holdings in shares of Qiagen by 39.8% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after acquiring an additional 243 shares in the last quarter. CWM LLC boosted its position in shares of Qiagen by 12.0% during the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after acquiring an additional 269 shares during the last quarter. Finally, Headlands Technologies LLC grew its holdings in shares of Qiagen by 396.6% during the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock worth $113,000 after purchasing an additional 2,189 shares in the last quarter. 70.00% of the stock is owned by institutional investors.

Qiagen Stock Performance

NYSE QGEN opened at $43.43 on Friday. The company has a 50-day simple moving average of $43.25 and a two-hundred day simple moving average of $43.73. Qiagen has a 12-month low of $39.03 and a 12-month high of $47.44. The firm has a market cap of $9.91 billion, a price-to-earnings ratio of 111.36, a PEG ratio of 3.39 and a beta of 0.41. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on QGEN. HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research note on Thursday, October 17th. Robert W. Baird raised their price objective on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Finally, Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $50.88.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.